Executive SummaryRandomized, placebo-controlled study on long-term efficacy of sorbinil, published in the Sept. 1 New England Journal of Medicine. Study concludes that the aldose reductase inhibitor, "as a metabolic intervention targeted against a specific biochemical consequence of hyperglycemia, can improve the neuropathologic lesions of diabetic neuropathy." The study is part of the Pfizer/National Eye Institute's large, multicenter investigation of sorbinil. It found that the 10 sorbinil-treated patients had a 42% decrease in nerve sorbitol content and a 3.8 fold increase in the percentage of regenerating myelinated nerve fibers after one-year of treatment. Pfizer said it expects analysis of all sorbinal trial data to be completed later this year. The company has begun considering related compounds.
You may also be interested in...
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?